[Abstract Only] Randomized Trial: Cabazitaxel vs. Abiraterone or Enzalutamide in Metastatic Prostate Cancer
23 Jan, 2020 | 01:48h | UTCCabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: ESMO 2019: Cabazitaxel vs Abiraterone or Enzalutamide in Previously Treated Metastatic Castration-Resistant Prostate Cancer – The ASCO Post (free)
Related Commentary on Twitter
#VisualAbstract: Cabazitaxel in Metastatic Prostate Cancer. See more NEJM Visual Abstracts now: pic.twitter.com/nUeb6dqRYi
— NEJM (@NEJM) December 26, 2019